Iovance Biotherapeutics (IOVA) to Release Quarterly Earnings on Thursday

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $72.17 million for the quarter. Parties that wish to register for the company's conference call can do so using this link.

Iovance Biotherapeutics Price Performance

Shares of NASDAQ:IOVA traded up $0.17 during midday trading on Friday, reaching $5.78. The company had a trading volume of 10,890,669 shares, compared to its average volume of 6,926,114. The stock's fifty day moving average price is $6.44 and its 200-day moving average price is $8.70. The stock has a market capitalization of $1.76 billion, a P/E ratio of -3.88 and a beta of 0.53. Iovance Biotherapeutics has a one year low of $5.05 and a one year high of $18.33.

Wall Street Analysts Forecast Growth

A number of research firms have commented on IOVA. Piper Sandler decreased their price objective on shares of Iovance Biotherapeutics from $10.00 to $7.50 and set a "neutral" rating for the company in a report on Friday, January 31st. HC Wainwright reaffirmed a "buy" rating and issued a $32.00 price objective on shares of Iovance Biotherapeutics in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Iovance Biotherapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $21.07.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.